Published: 3 March 2022
Publications
Quarterly summary of recent safety communications
Published 3 March 2022
Prescriber Update 43(1): 11
March 2022
The table below is a summary of recent safety communications to health
care professionals and consumers,
published on the Medsafe
website.
Date |
Communication |
Topic |
|
COVID-19 |
Adverse events following immunisation with COVID-19 vaccines
|
20/02/22 |
Monitoring |
Buccaline
tablets: review of the benefits and risks under section 36 of
the Medicines Act 1981 |
19/02/22 |
Monitoring |
Update –
Pregabalin and the possible risk of bullous dermatitis and exfoliating
skin reactions |
16/02/22 |
Consultation |
Proposed warning and advisory statement relating to the harm
of opioid abuse, misuse, and dependence (closes 4 April
2022) |
15/02/22 |
Monitoring |
Update – Dihydrocodeine: review of risks and benefits
|
31/01/22 |
Dear Healthcare Professional Letter |
Ronapreve (casirivimab and imdevimab): reduced neutralisation
activity of the antibody combination against the full-length
S protein of the Omicron variant of COVID-19 (PDF, 217 KB,
3 pages) |
24/12/21 |
Dear Healthcare Professional Letter |
Important
information about Ronapreve (casirivimab and imdevimab) supplied
in New Zealand (PDF, 362 KB, 3 pages) |
22/12/21 |
Dear Healthcare Professional Letter |
Supply of new formulation of Comirnaty (COVID-19 Vaccine) in
New Zealand (PDF, 365 KB, 10 pages) |
22/12/21 |
Alert |
Medsafe
is issuing a warning not to use Goree Beauty Cream with Lycopene,
Goree Day and Night Beauty Cream Oil Free, and Golden Pearl
Beauty Cream - statement under section 98 of the Medicines Act
1981 |
20/12/21 |
Alert |
Reminder: Comirnaty vaccination (Pfizer COVID-19 vaccine) can
cause myocarditis and pericarditis |
06/12/21 |
Dear Healthcare Professional Letter |
Labelling exemption - Cuprior (trientine) 150 mg film-coated
tablet (PDF, 265 KB, 2 pages) |
03/12/21 |
Dear Healthcare Professional Letter |
Alecensa (alectinib) - Warnings and precautions and specific
dose modification guidance for management of haemolytic anaemia
(PDF, 243 KB, 2 pages) |
22/11/21 |
Dear Healthcare Professional Letter |
Distinguishing between Thrombosis and Thrombosis with Thrombocytopenia
(TTS) following COVID-19 (AstraZeneca and Janssen) vaccinations
(PDF, 291 KB, 3 pages) |
18/11/21 |
Dear Healthcare Professional Letter |
Update on tenecteplase supply shortage (PDF, 2 pages, 373
KB) |
17/11/21 |
Dear Healthcare Professional Letter |
Supply of COVID-19 Vaccine AstraZeneca in New Zealand (PDF,
3 pages, 215 KB) |